Immunologic monitoring and immunotherapy in Ewing's sarcoma
dc.contributor.author | Weese, James L. | en_US |
dc.contributor.author | Richardson, Rudy J. | en_US |
dc.contributor.author | Pomeroy, T. C. | en_US |
dc.contributor.author | McCoy, James L. | en_US |
dc.contributor.author | Oldham, Robert K. | en_US |
dc.contributor.author | Cannon, G. B. | en_US |
dc.contributor.author | Dean, Jack H. | en_US |
dc.contributor.author | Herberman, Ronald B. | en_US |
dc.date.accessioned | 2006-09-11T18:17:36Z | |
dc.date.available | 2006-09-11T18:17:36Z | |
dc.date.issued | 1978-07 | en_US |
dc.identifier.citation | Richardson, R. L.; Oldham, R. K.; Pomeroy, T. C.; Weese, J. L.; McCoy, J. L.; Cannon, G. B.; Dean, J. H.; Herberman, R. B.; (1978). "Immunologic monitoring and immunotherapy in Ewing's sarcoma." Cancer Immunology Immunotherapy 4(2): 87-94. <http://hdl.handle.net/2027.42/46861> | en_US |
dc.identifier.issn | 0340-7004 | en_US |
dc.identifier.issn | 1432-0851 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46861 | |
dc.description.abstract | Serial immunological monitoring was performed on 31 patients with Ewing's sarcoma who were on a randomized immunotherapy trial with BCG administered by dermal scarification with a Heaf gun. Patients were skin-tested for delayed hypersensitivity reactions (DCHR) to recall antigens and extracts of tumor cells, and with keyhole limpet hemocyanin (KLH). In vitro testing consisted of lymphocyte counts, percentages of cells forming rosettes with sheep erythrocytes at 29° C and at 4° C, and leukocyte migration inhibition to tuberculin (PPD) and to 3 M KCl extracts of tumor cells. At the time of diagnosis, nearly all patients had positive DCHR to mumps and streptococcal antigens and were negative to PPD. Neither the skin tests nor the lymphocyte counts at this time gave useful prognostic information. In tests during and after therapy, the patients who responded and remained free of detectable disease had a higher incidence of DCHR to KLH and of rosette values in the normal range than did the patients who developed recurrent disease. The BCG immunotherapy had no apparent effect on immunologic parameters except for conversion of reactions to PPD. | en_US |
dc.format.extent | 703397 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Immunology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Cancer Research | en_US |
dc.title | Immunologic monitoring and immunotherapy in Ewing's sarcoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA; Department of Surgery, University of Michigan, 48109, Ann Arbor, Mich, USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA; Laboratory of Immunodiagnosis, National Cancer Institute, Building 10, Room 8B11, 20014, Bethesda, Maryland, USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA; Division of Oncology, Department of Medicine, Vanderbilt University, 37232, Nashville, Tenn., USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA; Division of Oncology, Department of Medicine, Vanderbilt University, 37232, Nashville, Tenn., USA | en_US |
dc.contributor.affiliationother | Laboratory of Immunodiagnosis and Radiation Oncology Branch, National Cancer Institute, 20014, Bethesda, Maryland, USA; Department of Immunology, Litton-Bionetics, Inc., 20795, Kensington, Maryland, USA; University of Texas Health Science Center, 78229, San Antonio, Texas, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46861/1/262_2004_Article_BF00200108.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00200108 | en_US |
dc.identifier.source | Cancer Immunology Immunotherapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.